<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680207</article-id><article-id pub-id-type="doi">10.3390/v16121859</article-id><article-id pub-id-type="publisher-id">viruses-16-01859</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Construction of a Macrophage-Tropic Subtype C HIV-1-mGreenLantern Reporter Virus for Studies on HIV-1 Replication and the Impact of Methamphetamine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mofed</surname><given-names>Dina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-16-01859" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9349-4326</contrib-id><name><surname>Mandarino</surname><given-names>Angelo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01859" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xuhong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-viruses-16-01859" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4427-5271</contrib-id><name><surname>Lang</surname><given-names>Yuekun</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01859" ref-type="aff">1</xref><xref rid="fn1-viruses-16-01859" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3905-5485</contrib-id><name><surname>Gowripalan</surname><given-names>Anjali</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01859" ref-type="aff">1</xref><xref rid="fn2-viruses-16-01859" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4111-0604</contrib-id><name><surname>Kalpana</surname><given-names>Ganjam V.</given-names></name><xref rid="af2-viruses-16-01859" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Prasad</surname><given-names>Vinayaka R.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-16-01859" ref-type="aff">1</xref><xref rid="c1-viruses-16-01859" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Hammarskjold</surname><given-names>Marie-Louise</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01859"><label>1</label>Departments of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; <email>dina.mahmoud@einsteinmed.edu</email> (D.M.); <email>angelo.mandarino@einsteinmed.edu</email> (A.M.); <email>ylcgm@missouri.edu</email> (Y.L.); <email>anjali.gowripalan@gmail.com</email> (A.G.)</aff><aff id="af2-viruses-16-01859"><label>2</label>Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA; <email>xuhong.wu@einsteinmed.edu</email> (X.W.); <email>ganjam.kalpana@einsteinmed.edu</email> (G.V.K.)</aff><author-notes><corresp id="c1-viruses-16-01859"><label>*</label>Correspondence: <email>vinayaka.prasad@einsteinmed.edu</email></corresp><fn id="fn1-viruses-16-01859"><label>&#x02020;</label><p>Current address: Department of Veterinary Pathobiology, College of Veterinary Medicine, Columbia, MO 65211, USA.</p></fn><fn id="fn2-viruses-16-01859"><label>&#x02021;</label><p>Current address: Division of Immunology and Infectious Diseases, John Curtin School of Medical Research, Australian National University, Canberra 2601, Australia.</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1859</elocation-id><history><date date-type="received"><day>21</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>HIV-1 subtype C viruses are responsible for 50% of global HIV burden. However, nearly all currently available reporter viruses widely used in HIV research are based on subtype B. We constructed and characterized a replication-competent HIV-1 subtype C reporter virus expressing mGreenLantern. mGreenLantern sequences were inserted in-frame with Nef ATG in HIV-1<sub>IndieC1</sub>. As controls, we employed HIV-1<sub>IndieC1</sub>, HIV-1<sub>ADA</sub>, and HIV-1<sub>NLAD8-GFP-Nef</sub> viruses. HIV-1<sub>IndieC1-mGreenLantern</sub> (HIV-1<sub>IndieC1-mGL</sub>) exhibited characteristics of the parental HIV-1<sub>IndieC1</sub> virus, including its infectivity in TZMbl reporter cells and replication competence in macrophages. To further characterize HIV-1<sub>IndieC1-mGL</sub> virus, we tested its responsiveness to CCL2 levels, a characteristic feature of subtype B HIV-1 that is missing in subtype C. CCL2 immunodepletion inhibited the production of HIV-1<sub>ADA</sub> and HIV-1<sub>NLAD8-GFP-Nef</sub> as expected, but not that of HIV-1<sub>IndieC1-mGL</sub>, as previously reported. We also tested the effect of methamphetamine, as its effect is mediated by NF-kB and since subtype C viruses carry an additional copy of NF-kB. We found that methamphetamine increased the replication of all viruses tested in macrophages; however, its effect was much more robust for HIV-1<sub>IndieC1</sub> and HIV-1<sub>IndieC1-mGL</sub>. Our studies established that HIV-1<sub>IndieC1-mGL</sub> retains all the characteristics of the parental HIV-1<sub>IndieC1</sub> and can be a useful tool for HIV-1 subtype C investigations.</p></abstract><kwd-group><kwd>replication competent HIV-1 reporter</kwd><kwd>subtype C HIV-1</kwd><kwd>CCL2</kwd><kwd>methamphetamine</kwd></kwd-group><funding-group><award-group><funding-source>NIH</funding-source><award-id>R01-AI153008</award-id></award-group><award-group><funding-source>NIH</funding-source><award-id>T32 AI007501</award-id></award-group><funding-statement>This research was funded by NIH R01-AI153008 (to V.R.P.), and A.M. was funded by the institutional NIH training grant T32 AI007501.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01859"><title>1. Introduction</title><p>HIV-1 subtype C is responsible for a major share&#x02014;up to 50%&#x02014;of the global HIV burden [<xref rid="B1-viruses-16-01859" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01859" ref-type="bibr">2</xref>] and displays unique features among group M subtypes. Subtype B HIV-1, on the other hand, is responsible for only about 10% of the global HIV burden. Subtype C HIV-1 is the least fit of all group M HIV-1 subtypes and their circulating recombinant forms (CRFs) [<xref rid="B3-viruses-16-01859" ref-type="bibr">3</xref>,<xref rid="B4-viruses-16-01859" ref-type="bibr">4</xref>]. HIV-1 subtype C is also less likely to undergo a coreceptor usage switch, and hence, a greater proportion of viruses in people living with HIV are likely to be monocyte-tropic viruses [<xref rid="B5-viruses-16-01859" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01859" ref-type="bibr">6</xref>]. While most HIV-1 subtypes have two copies of NF-&#x003ba;B enhancer in their long terminal repeats (LTRs), subtype C viruses have three NF-&#x003ba;B binding sites in their LTRs, leading to higher transcriptional activity in vitro and higher viral loads in people living with HIV-1. In fact, reports have shown the appearance of a fourth, novel NF&#x003ba;B variant in HIV-1C viruses in India [<xref rid="B7-viruses-16-01859" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01859" ref-type="bibr">8</xref>]. HIV-1 Gag p6 contains two late motifs&#x02014;PTAP and LYPX&#x02014;which recruit the cellular endosomal sorting complexes required for transport (ESCRT) machinery protein TSG101 or the ESCRT adaptor protein ALIX, respectively, to the virion assembly sites. TSG101 or ALIX both recruit ESCRT III proteins termed charged multivesicular body (CHMP) proteins, which bring about membrane fission at the bud neck and facilitate virus release [<xref rid="B9-viruses-16-01859" ref-type="bibr">9</xref>]. Duplication of the PTAP motif is rarely observed in subtype B viruses in infected individuals [<xref rid="B10-viruses-16-01859" ref-type="bibr">10</xref>]. In contrast, in HIV-1 subtype C-infected individuals, PTAP duplication is seen in up to 30% of infected individuals [<xref rid="B11-viruses-16-01859" ref-type="bibr">11</xref>]. Additionally, a functional LYPX motif is absent in nearly all HIV-1 subtype C HIV-1 due to an LY dipeptide deletion [<xref rid="B12-viruses-16-01859" ref-type="bibr">12</xref>,<xref rid="B13-viruses-16-01859" ref-type="bibr">13</xref>]. However, it has been reported that in some antiretroviral treatment failure cases, variant viruses emerge containing a PYxE tetrapeptide sequence [<xref rid="B14-viruses-16-01859" ref-type="bibr">14</xref>]. Such acquired PYxE insertions restore binding to ALIX, increase virus fitness, and restore increased virus budding in response to CCL2 signaling [<xref rid="B12-viruses-16-01859" ref-type="bibr">12</xref>]. Furthermore, while all other HIV-1 subtypes retain a highly conserved dicysteine motif in the Tat protein that is part of a conserved feature between HIV-1 Tat proteins and &#x003b2;-chemokines, HIV -1 subtype C lacks this feature due to a C31S substitution in the dicysteine motif [<xref rid="B15-viruses-16-01859" ref-type="bibr">15</xref>].</p><p>Genetically engineered reporter HIV-1 constructs have allowed researchers to monitor the kinetics of infection and replication in vitro. Over the years, a large number of recombinant reporter viruses have been designed, developed, and used as tools to study various aspects of HIV-1 replication. Interestingly, a vast majority of these vectors have been based on HIV-1 subtype B. Reporter viruses carrying the <italic toggle="yes">luciferase</italic> gene are used to monitor virus-cell membrane fusion [<xref rid="B16-viruses-16-01859" ref-type="bibr">16</xref>], nuclear entry, loss of capsid integrity, and uncoating [<xref rid="B17-viruses-16-01859" ref-type="bibr">17</xref>]. Reporter viruses carrying luciferase or green fluorescent protein (GFP) have been used to determine the infectivity of HIV-1 variants, to test their sensitivity to antiretrovirals, to study viral tropism, or to understand the immunological responses to infection. Reporter viruses with <italic toggle="yes">Nef</italic> substitutions are generally used to study early events, while Gag-fusion reporter vectors are designed to study both early and late events of virus assembly and release [<xref rid="B18-viruses-16-01859" ref-type="bibr">18</xref>]. Reporter viruses containing fluorescent proteins fused to Vpr or envelope proteins have also been generated to visualize and measure virion production and release. The Vpr-GFP fusion protein helps monitor HIV-1 virions released via fluorescence microscopy or flow cytometry, allowing real-time tracking of viral release and high-throughput screening for factors influencing viral release [<xref rid="B19-viruses-16-01859" ref-type="bibr">19</xref>]. The use of Gaussia luciferase fusion with HIV-1 envelope protein allows detection of low levels of virion release. Similarly, NanoLuc-containing bioluminescent HIV-1 reporter viruses facilitated high sensitivity measurement of virus particle production. Kirui and Freed [<xref rid="B20-viruses-16-01859" ref-type="bibr">20</xref>] showed how the use of this new reporter virus enhances the efficacy of quantification. More recently, dual reporter viruses have been developed to separately monitor the expression of LTR-dependent and LTR-independent reporter genes to monitor the time to latency from the time of infection [<xref rid="B21-viruses-16-01859" ref-type="bibr">21</xref>]. The HIV-1 reporter viruses mentioned above are only a fraction of a larger number that have been reported over the years and that are in use currently. It is unusual that, currently, there is only one reporter virus based on HIV-1 subtype C [<xref rid="B22-viruses-16-01859" ref-type="bibr">22</xref>] despite the fact that half of the global HIV burden is due to this subtype of HIV-1. Reporter viruses exemplified by the ones mentioned above have helped vastly advance our knowledge of the biology and pathogenesis of HIV-1 subtype B. A similar progress with subtype C viruses is much needed.</p><p>In this study, we generated a mGreenLantern-tagged full-length and replication-competent HIV-1<sub>IndieC1</sub> reporter virus clone [<xref rid="B23-viruses-16-01859" ref-type="bibr">23</xref>] for studies in myeloid cells. First, we established that the infectivity and replication competence in macrophages of HIV-1<sub>IndieC1-mGreenLantern</sub> (HIV-1<sub>IndieC1-mGL</sub>) virus was similar to that of the parental virus. Second, we investigated whether the new reporter virus retains a characteristic feature of HIV-1 subtype C viruses, namely an inability to respond to CCL2-mediated modulation of virus production, which is due to the characteristic absence of a functional LYPX motif in the Gag p6 late domain of subtype C HIV-1 isolates. We previously showed that CCL2 treatment stimulates the mobilization of ALIX from the F-actin cytoskeleton to the cytoplasm, making it possible for HIV-1 Gag to recruit ALIX efficiently and enhance budding [<xref rid="B12-viruses-16-01859" ref-type="bibr">12</xref>]. Due to the lack of LYPX motif on subtype C HIV-1 Gag protein, subtype C viruses are unable to respond to CCL2 in the media to enhance virus production via increased budding. It has also been shown that blocking CCL2-signaling via the addition of anti-CCL2, which leads to a near complete colocalization of ALIX with F-actin structures, causes a strong inhibition of virus production (6&#x02013;10 fold). We tested the new reporter virus for its ability to respond to CCL2 or anti-CCL2 treatment and found that the virus production is not modulated by the levels of CCL2 present in the medium. Finally, we tested the responsiveness of the new HIV-1 subtype C reporter to methamphetamine (Meth). We report that HIV-1 subtype C virus replication is enhanced by Meth, and the increase is to a much higher level than that observed in HIV-1 subtype B.</p></sec><sec id="sec2-viruses-16-01859"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-16-01859"><title>2.1. Cells, Cell Lines, and Infectious Clones of HIV-1</title><p>The 293T cells were obtained from ATCC and TZM-bl cells from the NIH AIDS Reagent Repository. Both cell types were maintained in Dulbecco&#x02019;s Modified Eagle Medium (DMEM) (Gibco, Thermofisher Scientific, New York, NY, USA) supplemented with 10% FBS (Gibco, Thermofisher Scientific, NY, USA) and 1% Penicillin-Streptomycin (Gibco, Thermofisher Scientific, NY, USA) and incubated at 37 &#x000b0;C with 5% CO<sub>2</sub>. Human monocyte-derived macrophages (MDMs) were obtained by differentiating CD14<sup>+</sup> monocytes isolated from peripheral blood mononuclear cells (PBMCs) by negative selection (MojoSort Human Pan Monocyte isolation kit, catalog number, 480060, Thermofisher Scientific, NY, USA). Negative selection protocol utilizes beads carrying antibodies to cell surface markers on blood cell types that are not needed, such as T and B lymphocytes, and granulocytes such as neutrophils, eosinophils, basophils, and platelets. Thus, the protocol yields only CD14+ CD16- monocytes. PBMCs were purified from blood samples from the New York Blood Center.</p></sec><sec id="sec2dot2-viruses-16-01859"><title>2.2. Plasmids</title><p>pIndieC1 was a gift from U. Ranga, pNLAD8-GFPNef was a gift from J. Karn, and pADA was a gift from K. Peden. The pcDNA 3.1-mGreenLantern and pEF1a-IRES-Neo were from Addgene.</p></sec><sec id="sec2dot3-viruses-16-01859"><title>2.3. Construction of HIV-1<sub>IndieC1-mGL</sub> Reporter Virus</title><p>The mGreenLantern-IRES cassette was inserted into the backbone of pIndieC1 by overlap extension PCR [<xref rid="B24-viruses-16-01859" ref-type="bibr">24</xref>] as follows. Fragment 1 (2614 bp) represents a part of gp160 starting from <italic toggle="yes">Pac I</italic> restriction site, fragment 2 represents mGreenLantern (720 bp) from pcDNA3.1-mGreenLantern [<xref rid="B25-viruses-16-01859" ref-type="bibr">25</xref>], fragment 3 represents IRES (553 bp) derived from pEF1a-IRES-Neo [<xref rid="B26-viruses-16-01859" ref-type="bibr">26</xref>], fragment 4 represents <italic toggle="yes">Nef</italic> (624 bp), and fragment 5 represents the rest of the pIndieC backbone (3575 bp), which ends at the <italic toggle="yes">AatII</italic> restriction site. Using repeat sequences that were built-in at the joining ends, fragments I and II were combined by overlap extension PCR, followed by sequentially adding fragments III, IV, and V all via successive overlap extension PCR reactions to the 3&#x02032; end of the product of the previous overlap extension PCR step. All PCR reactions were performed using Q5 High-fidelity DNA polymerase (New England Biolabs). Primers used for PCR reactions are listed in <xref rid="viruses-16-01859-t001" ref-type="table">Table 1</xref>. The final 8 kb product (<italic toggle="yes">Pac1</italic>-gp160-mGreenLantern-IRES-Nef-LTR-<italic toggle="yes">AatII</italic>) was digested with <italic toggle="yes">Pac I</italic> and <italic toggle="yes">Aat II</italic> and ligated to the 6.7 kb <italic toggle="yes">Pac I</italic>-<italic toggle="yes">AatII</italic> fragment derived from parental pIndieC1 plasmid to recreate the entire virus clone with the mGreenLantern reporter gene (<xref rid="viruses-16-01859-f001" ref-type="fig">Figure 1</xref>). The presence of mGreenLantern-IRES in the final pIndieC1-mGreenLantern plasmid and the absence of undesired mutations were validated via nanopore (Plasmidsaurus, Eugene, OR, USA) and Sanger sequencing.</p></sec><sec id="sec2dot4-viruses-16-01859"><title>2.4. Generating High-Titer Virus Stocks and Testing Their Infectivity</title><p>CD14<sup>+</sup> monocytes were plated with Monocyte attachment medium (PromoCell, Heidelberg, Germany) and differentiated into macrophages by adding DMEM supplemented with 10% FBS, 1% Penicillin-Streptomycin, and recombinant human macrophage colony stimulating factor (rhM-CSF; 5 ng/mL, Peprotech, Themo Fisher, Rocky Hill, NJ, USA, Catalog number, AF-300&#x02013;25) and then grown in a cell culture incubator for ten days.</p><p>To generate high-titer viruses, plasmid DNAs of infectious molecular clones HIV-1<sub>ADA</sub> (subtype B) [<xref rid="B27-viruses-16-01859" ref-type="bibr">27</xref>], HIV-1<sub>IndieC1</sub> (subtype C) [<xref rid="B23-viruses-16-01859" ref-type="bibr">23</xref>], HIV-1<sub>NLAD8-GFP-Nef</sub> [<xref rid="B28-viruses-16-01859" ref-type="bibr">28</xref>], and HIV-1<sub>IndieC1-mGL</sub> reporter were transfected separately (20 &#x000b5;g each) into 293T cells seeded at a density of 10 &#x000d7; 10<sup>6</sup> cells in a 10 cm plate using Lipofectamine 3000 (Invitrogen, ThermoFisher, Waltham, MA, USA). Media containing infectious viruses were collected at 24 h post transfection for p24 measurement. The p24 levels were measured using an AlphaLisa detection kit (Perkin Elmer, Waltham, MA, USA, cat #AL291F) for HIV-1<sub>ADA</sub> and HIV-1<sub>NLAD8-GFP-Nef</sub> (subtype B) or using the HIV-1 p24 Antigen Capture Assay kit (ABL, Rockville, MD, USA; Catalog number, 5421) for HIV-1<sub>IndieC1</sub> and HIV-1<sub>IndieC1-mGL</sub> (subtype C). The infectivity of viruses thus generated was tested using TZM-bl luciferase assay. Briefly, TZM-bl cells were seeded in 12-well plates at a density of 2 &#x000d7; 10<sup>5</sup> cells per well and incubated at 37 &#x000b0;C with 5% CO<sub>2</sub> for 24 h. Cells were infected with each of the four HIV-1 viruses mentioned above at increasing multiplicities of infection (MOI). In this study, we define MOI as ng of p24 of HIV per 2 &#x000d7; 10<sup>5</sup> target cells. We used MOIs equivalent to 31.25, 62.5, 125, 250, and 500 ng p24 per 2 &#x000d7; 10<sup>5</sup> cells and incubated them at 37 &#x000b0;C with 5% CO<sub>2</sub> for 24 h. Cells were washed twice with 1xXPBS and lysed using lysis buffer in the Luciferase assay kit (Promega, Madison, WI, USA). For each virus, 50 &#x003bc;L of cell lysate each were used to measure the luciferase activity.</p></sec><sec id="sec2dot5-viruses-16-01859"><title>2.5. Multiday HIV-1 Replication Assay in Monocyte-Derived Macrophages</title><p>Macrophage infection and replication of HIV-1<sub>ADA</sub>, HIV-<sub>1NLAD8-GFP-Nef</sub> reporter, HIV-1<sub>IndieC1</sub>, and HIV-1<sub>IndieC1-mGL</sub> reporter viruses were tested in monocyte-derived macrophages (MDMs). Briefly, CD14<sup>+</sup> monocytes were seeded in 6-well plates at a density of 1 &#x000d7; 10<sup>6</sup> cells per well and differentiated into macrophages, as described above. MDMs were infected with each of the four different viruses separately at 10 ng p24 per 10<sup>6</sup> cells. Half of the media (1 mL) was removed and replenished with fresh medium every three days throughout the multiday replication experiment. Replication competence was determined by measuring p24 in cultured infected media. All MDM experiments were performed three times. Each experiment used MDMs from a separate donor, and two experimental replicates were used to calculate an average per donor. Thus, the data in each case are represented as mean &#x000b1; SEM from three separate samples (<italic toggle="yes">n</italic> = 3).</p></sec><sec id="sec2dot6-viruses-16-01859"><title>2.6. Measuring the Effect of CCL2 and Anti-CCL2 on the Replication of HIV-1 Isolates</title><p>To determine the effect of CCL2 and anti-CCL2 on the replication of HIV-1, 1 &#x000d7; 10<sup>6</sup> MDMs were infected with HIV-<sub>1NLAD8-GFP-Nef</sub> and HIV-1<sub>IndieC1-mGL</sub> reporter viruses at 10 ng p24 per 10<sup>6</sup> cells. Infected MDMs were treated with CCL2 (250 ng/mL; PeproTech, Themo Fisher, Rocky Hill, NJ, USA, Catalog number, 300-04-20UG), anti-CCL2 (2.5 mg/mL; PeproTech, Themo Fisher, Rocky Hill, NJ, USA, Catalog number, 500-M71-500UG), or an isotype control antibody from unimmunized mice (IgG2a, kappa; 2.5 mg/mL; PeproTech, Themo Fisher, Rocky Hill, NJ, USA, Catalog number, 500-M00) [<xref rid="B12-viruses-16-01859" ref-type="bibr">12</xref>]. Half the media and all the treatments were replenished every 3 days for 30 days. Replication of HIV-<sub>1NLAD8-GFP-Nef</sub> and HIV-1<sub>IndieC1-mGL</sub> reporter viruses was monitored by tracking the levels of cellular green fluorescence using an inverted fluorescence microscope (Zeiss Axio Observer, Carl Zeiss, Oberkochen, Germany) or by measuring p24 levels in the cultured infected media as mentioned above.</p></sec><sec id="sec2dot7-viruses-16-01859"><title>2.7. Measuring the Effect of Methamphetamine on the Replication of HIV-1 Isolates</title><p>To investigate the effect of Meth on the HIV-1 (subtype B and subtype C) replication, MDMs were seeded in 6-well plates at a density of 1 &#x000d7; 10<sup>6</sup> cells/well and infected at day 10 with HIV-1<sub>ADA</sub>, HIV-1<sub>NLAD8-GFP-Nef</sub>, HIV-1<sub>IndieC1</sub>, or HIV-1<sub>IndieC1-mGL</sub> viruses, respectively, at 10 ng p24/10<sup>6</sup> cells. Infected MDMs were treated with Meth (Sigma-Aldrich, St. Louis, MO, USA, catalog number, 51-57-0) at three different concentrations (100, 250, and 500 &#x003bc;M). Every three days, half the media was replenished with new media containing fresh Meth for 15 days. The effect of Meth on viral replication was determined by monitoring p24 production in the media for all infected viruses as well as by tracking the intensity green fluorescence (Zeiss Axio Observer, Carl Zeiss, Oberkochen, Germany) for HIV-1<sub>IndieC1-mGL</sub> and HIV-<sub>1NLAD8-GFP-Nef</sub> viruses.</p></sec><sec id="sec2dot8-viruses-16-01859"><title>2.8. Quantification of Fluorescence Intensity</title><p>Cellular green fluorescence resulting from the expression of fluorescent proteins (GFP or mGreenLantern) upon HIV infection was quantified using a Zeiss Axio Observer epifluorescence microscope at magnification (20&#x000d7;). Images were captured at the center of the well, with an average of 50 cells imaged for each reporter virus. We used NIH Image J software (NIH Image Manual (V1.61)) to quantify the fluorescence intensity image. Intensities for each time point were calculated from images taken from three replicates and plotted in respectively.</p></sec><sec id="sec2dot9-viruses-16-01859"><title>2.9. Statistical Analysis</title><p>At least three independent replicates were carried out for each experiment, and the mean was calculated in all cases. Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA).</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01859"><title>3. Results</title><sec id="sec3dot1-viruses-16-01859"><title>3.1. Construction of HIV-1<sub>IndieC1mGL</sub> Reporter Virus</title><p>We inserted the sequences encoding mGreenLantern at the beginning of the <italic toggle="yes">Nef</italic> gene of an infectious molecular clone of HIV-1<sub>IndieC1</sub> such that the ATG at the start of <italic toggle="yes">Nef</italic> open reading frame (orf) would be the initiation codon for mGreenLantern. An internal ribosomal entry site (IRES) sequence was inserted upstream of <italic toggle="yes">Nef</italic> gene while restoring its ATG site to ensure that <italic toggle="yes">Nef</italic> expression would be unaffected. No additional modifications were made to HIV-1<sub>IndieC1</sub>. <xref rid="viruses-16-01859-f001" ref-type="fig">Figure 1</xref> shows the position of mGreenLantern insertion and the IRES sequence inserted in the HIV-1<sub>IndieC1</sub> construct in comparison with the parental HIV-1<sub>IndieC1</sub> clone. The reporter construct was sequenced via both nanopore sequencing of the whole viral construct and Sanger sequencing to resolve any ambiguities. The sequencing confirmed that the construct included the intended modifications and no undesired mutations.</p></sec><sec id="sec3dot2-viruses-16-01859"><title>3.2. HIV-1 <sub>IndieC1-mGL</sub> Reporter Virus Is a Replication Competent Virus</title><p>We wished to test the infectivity and replication competence of the new reporter virus HIV-1<sub>IndieC1-mGL</sub>. We prepared high-titer virus stocks of HIV-1<sub>IndieC1-mGL</sub> and its parental HIV-1<sub>IndieC1</sub> virus. For comparison, we also generated virus stocks of a subtype B reporter virus, HIV-1<sub>NLAD8-GFP-Nef</sub>, and its parental virus HIV-1<sub>ADA</sub>. First, we tested the infectivity of these four viruses employing the TZM-bl luciferase assay. TZM-bl cells carry an integrated copy of the luciferase reporter gene under the control of HIV-1 LTR [<xref rid="B29-viruses-16-01859" ref-type="bibr">29</xref>] and thus respond with the induction of luciferase activity that corresponds to the degree of infection. TZM-bl cells were infected with increasing virus inputs for each of the four viruses. The results indicated that the infectivity of the HIV-1<sub>IndieC1-mGL</sub> reporter virus was comparable to its parental virus HIV-1<sub>IndieC1</sub> (<xref rid="viruses-16-01859-f002" ref-type="fig">Figure 2</xref>A). In our comparison of the infectivity of the subtype B virus (HIV-1<sub>ADA</sub>) and the subtype B reporter virus, HIV-1<sub>NLAD8-GFP-Nef</sub>, the reporter virus was consistently higher than that of HIV-1<sub>ADA</sub> by about 2-fold at all multiplicities of infection (<xref rid="viruses-16-01859-f002" ref-type="fig">Figure 2</xref>B). This is likely due to the chimeric derivation of this virus [<xref rid="B28-viruses-16-01859" ref-type="bibr">28</xref>]. The HIV-1<sub>NLAD8-GFP-Nef</sub> virus is based on HIV-1<sub>NL4-3</sub> provirus but replaces the <italic toggle="yes">env</italic> gene with that from HIV-1<sub>ADA</sub>. As the only common feature between HIV-1<sub>ADA</sub> and HIV-1<sub>NLAD8-GFP-Nef</sub> is the <italic toggle="yes">env</italic> gene of HIV-1<sub>ADA</sub>, the robustness of the virus may be attributable to sequences outside <italic toggle="yes">env</italic>.</p><p>Next, we examined the replication competence of the HIV-1 subtype C reporter virus alongside control viruses (HIV-1<sub>IndieC1</sub>, HIV-1<sub>ADA</sub>, and HIV-1<sub>NLAD8-GFP-Nef</sub>) in MDMs in a 30-day replication assay. We observed a delay in virus replication for HIV-1<sub>IndieC1mGL</sub> when compared to the parental HIV-1<sub>IndieC1</sub> virus (day 18 peak p24 production vs. day 15; <xref rid="viruses-16-01859-f003" ref-type="fig">Figure 3</xref>A left panel). This is not surprising considering the two macro changes made to the virus genome, which may have affected some aspect of the genome RNA or any of the downstream functions of the genome, with a consequent effect on the virus progeny population that manifested in a 3-day delay. It is well known that HIV-1 subtype C viruses replicate at a lower efficiency than subtype B viruses. Accordingly, we found that both HIV-1<sub>ADA</sub> and HIV-1<sub>NLAD8-GFP-Nef</sub> viruses replicated at a higher rate, reaching a peak virus production that was about 3-fold higher than subtype C viruses (compare <xref rid="viruses-16-01859-f003" ref-type="fig">Figure 3</xref>A,B). Collectively, the results of the p24 to infectivity ratios (relative luminescence units of luciferase activity to ng p24) and the replication-competence experiment show that the HIV-1<sub>IndieC1-mGL</sub> is a replication-competent virus similar to the parental HIV-1<sub>IndieC1</sub>.</p></sec><sec id="sec3dot3-viruses-16-01859"><title>3.3. Production of HIV-1<sub>IndieC1-mGL</sub> in MDMs Is Not Responsive to CCL2 Levels</title><p>Previous reports showed that CCL2 immuno-depletion suppresses HIV-1 subtype B replication in macrophages [<xref rid="B12-viruses-16-01859" ref-type="bibr">12</xref>,<xref rid="B30-viruses-16-01859" ref-type="bibr">30</xref>] and that the addition of CCL2 enhances virus replication [<xref rid="B12-viruses-16-01859" ref-type="bibr">12</xref>]. We showed that this CCL2-dependent modulation of HIV-1 replication was due to the mobilization of ALIX from F-actin stress fibers to the soluble cytoplasm by CCL2 signaling, and this required the presence of late domain motif LYPX in Gag p6, which is responsible for ALIX recruitment to virus assembly and budding sites on the plasma membrane. Furthermore, we reported that 99.8% of the 495 full-length subtype C virus sequences tested lacked a functional LYPX motif due to a highly conserved LY dipeptide deletion in Gag p6. Thus, the subtype C virus HIV-1<sub>IndieC1</sub> was unresponsive to levels of CCL2 in the media due to its inability to recruit ALIX [<xref rid="B12-viruses-16-01859" ref-type="bibr">12</xref>]. Since the efficiency of the budding and release of virus particles is not responsive to the levels of CCL2 in HIV-1 subtype C viruses, we tested the HIV-1<sub>IndieC1-mGL</sub> reporter virus for its CCL2 responsiveness. We infected MDMs with either HIV-1<sub>IndieC1-mGL</sub> or the parental HIV-1<sub>IndieC1</sub> virus. For each virus, four separate conditions were employed, namely untreated, CCL2 treated, anti-CCL2 treated, or isotype control IgG-treated, and the virus particle release was measured over a period of 30 days. Like before, we observed a 3-day delay in the replication of HIV-1<sub>IndieC1mGL</sub> virus (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>A, Left panal).</p><p>MDMs infected with either HIV-1<sub>NLAD8-GFP-Nef</sub> or HIV-1<sub>IndieC1-mGL</sub> virus displayed an increase (virus production peak on 18 days instead of 15 days post infection). We also included a subtype B control HIV-1<sub>NLAD8-GFP-Nef</sub>, which showed virus production at 15 days post infection. Importantly, anti-CCL2 treatment resulted in a substantial reduction (~6-fold) in the production of subtype B virus compared to untreated infected MDMs or isotype antibody control (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>A, right panel). Similarly, CCL2 treatment enhanced the production of subtype B viruses by ~1.8-fold compared to untreated or isotype antibody-treated MDMs (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>A, right panel). In contrast, virus production levels for HIV-1<sub>IndieC1mGL</sub>, as expected, were unaffected by levels of CCL2 in the medium (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>A, left panel).</p><p>In addition to monitoring p24 production, we also quantified mGreenLantern or GFP fluorescence, respectively, for cells infected with HIV-1<sub>IndieC1-mGL</sub> and HIV-1<sub>NLAD8-GFP-Nef</sub> viruses, respectively. A gradual increase was observed in the total fluorescence intensity from the time of infection to day 15 post infection. For HIV-1<sub>NLAD8-GFP-Nef</sub>, treatment with anti-CCL2 led to a considerable reduction in GFP fluorescence compared to untreated or isotype antibody-treated, infected MDMs (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>C). Similarly, treatment with CCL2 led to an increase in GFP fluorescence throughout the culture up to day 15 (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>C), as reported previously [<xref rid="B12-viruses-16-01859" ref-type="bibr">12</xref>]. In contrast, addition of CCL2, anti-CCL2, or the isotype control antibody did not change the fluorescence intensity of HIV-1<sub>IndieC1-mGL</sub>-infected MDMs (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>B). A fluorescence intensity plot for each treatment (e.g., +CCL2, +anti-CCL2, or +Isotype antibody control) for infection with each reporter virus (HIV-1<sub>IndieC1-mGL</sub> or HIV-1<sub>NLAD8-GFP-Nef</sub>) showed results consistent with the observation that the subtype C reporter is refractory to CCL2 levels, unlike the subtype B reporter virus (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>D, compare left and right panels). Furthermore, the pattern of responsiveness to CCL2 levels by the two reporter viruses (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>D) was similar to that seen when the p24 production was plotted (<xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>A). These results together indicate that the replication pattern of the newly created HIV-1<sub>IndieC1-mGL</sub> follows the patten of the wildtype HIV-1<sub>IndieC1</sub> and that the replication of this virus can be monitored by measuring p24 as well as by imaging and by quantitating mGreenLantern fluorescence.</p></sec><sec id="sec3dot4-viruses-16-01859"><title>3.4. Methamphetamine Treatment Markedly Enhanced HIV-1 Subtype C Replication in MDMs</title><p>Previous studies have reported that Meth increases HIV-1 replication in macrophages [<xref rid="B31-viruses-16-01859" ref-type="bibr">31</xref>,<xref rid="B32-viruses-16-01859" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01859" ref-type="bibr">33</xref>]. Meth is known to trigger the NF-kB signaling pathway in immune cells, including macrophages, and thus, its impact on HIV-1 replication is mediated by enhanced LTR transcription [<xref rid="B22-viruses-16-01859" ref-type="bibr">22</xref>]. Since HIV-1 subtype C viruses contain 3 NF-kB sites, we chose to study the impact of Meth on subtype C replication in MDMs, employing the HIV-1<sub>IndieC1-mGL</sub> reporter virus. We infected MDMs, in parallel, with HIV-1<sub>ADA</sub>, HIV-1<sub>NLAD8-GFP-Nef</sub>, HIV-1<sub>IndieC1</sub>, and HIV-1<sub>IndieC1-mGL</sub> viruses in the presence or absence of Meth. As indicated by increased levels of p24 measured at various times after infection up to day 15, Meth treatment enhanced the replication of all viruses compared to untreated HIV-infected MDMs (<xref rid="viruses-16-01859-f005" ref-type="fig">Figure 5</xref>). However, the increase was more robust for HIV-1 subtype C viruses compared to subtype B viruses (compare <xref rid="viruses-16-01859-f005" ref-type="fig">Figure 5</xref>A, top panels to bottom panels). Also, we noticed that the highest increase in the replication of HIV-1 (subtype C and B) by Meth was observed at a concentration of 100 &#x003bc;M, while the increases were progressively lower at 250 and 500 &#x003bc;M, respectively. For example, the increase in p24 levels in the presence of Meth over its absence for HIV-1<sub>IndieC-mGL</sub> was ~4.5-fold at 100 &#x003bc;M, 3.7-fold at 250 &#x003bc;M, and 2.6-fold at 500 &#x003bc;M (<xref rid="viruses-16-01859-f005" ref-type="fig">Figure 5</xref>A, top right). Increases for HIV-1<sub>IndieC1</sub> were remarkably similar to that observed for HIV-1<sub>IndieC-mGL</sub> at each of the three Meth concentrations (<xref rid="viruses-16-01859-f005" ref-type="fig">Figure 5</xref>A, top left). The increases in virus replication for HIV-1<sub>ADA</sub> or HIV-1<sub>NLAD8-GFP-Nef</sub> were lower than subtype C viruses: 3- or 3.8-fold at 100 &#x003bc;M, 2.2- or 2.7-fold at 250 &#x003bc;M, and 1.4- or 1.7-fold at 500 &#x003bc;M, respectively (<xref rid="viruses-16-01859-f005" ref-type="fig">Figure 5</xref>A, bottom panels).</p><p>To determine if fluorescence intensity of the infected cells reflects the observed Meth-induced increase in replication of the viruses, we also compared the results of cellular green fluorescence intensity in MDMs infected with HIV-1<sub>IndieC1-mGL</sub> or HIV-1<sub>NLAD8-GFP-Nef</sub> in the presence or absence of Meth at three different concentrations (100, 250, and 500 &#x003bc;M). First, we noted that both viruses seem to display a similar level of fluorescence intensity despite the fact that mGreenLantern is 6-fold brighter than GFP. The reasons for this are that HIV-1<sub>NLAD8-GFP-Nef</sub> virus replicates much more robustly than HIV-1<sub>IndieC1mGL</sub> both because subtype B viruses replicate better than subtype C but also because the chimeric nature of HIV-1<sub>NLAD8-GFP-Nef</sub> virus replicates to higher levels, as mentioned above. We therefore made comparisons (only within each virus not between the viruses) of green fluorescence intensity in the presence of Meth compared to its absence (<xref rid="viruses-16-01859-f005" ref-type="fig">Figure 5</xref>B). The increase in fluorescence intensity observed over no Meth was much higher for HIV-1<sub>IndieC1-mGL</sub> (<xref rid="viruses-16-01859-f005" ref-type="fig">Figure 5</xref>C, left panel) than for HIV-1<sub>NLAD8-GFP-Nef</sub> (<xref rid="viruses-16-01859-f005" ref-type="fig">Figure 5</xref>C, right panel). We noted that the fluorescence intensities of GFP and mGreenLantern are intrinsically different. Therefore, the comparisons were made between treatments with and without Meth but within either HIV-1<sub>IndieC1-mGL</sub> alone or HIV-1<sub>NLAD8-GFP Nef</sub> alone. These findings strongly suggest that the impact of Meth on HIV-1 subtype C replication is enhanced to a higher level than subtype B due to the additional NF-kB binding site in the LTR of HIV-1<sub>IndieC1</sub> or HIV-1<sub>IndieC1-mGL</sub>.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01859"><title>4. Discussion</title><p>In this study, we constructed a HIV-1 subtype C virus expressing mGreenLantern via the spliced <italic toggle="yes">Nef</italic> mRNA. mGreenLantern is a GFP derivative that has been optimized for efficient folding and rapid expression [<xref rid="B25-viruses-16-01859" ref-type="bibr">25</xref>]. As a result, mGreenLantern is six times brighter than EGFP. As the reporter virus was based on the macrophage-tropic HIV-1<sub>IndieC1</sub>, this virus would be useful for studying HIV-1 replication in myeloid cells (monocytes, macrophages, and microglia). The design of this reporter virus will facilitate translation of the Nef protein from the primary, unspliced mRNA as well as from all spliced mRNAs due to the IRES inserted downstream of mGreenLantern. This new reporter virus allows one to track HIV-1 replication by monitoring mGreenLantern expression in the target cells. This method provides a straightforward visual indicator of infection, allowing for efficient tracking and analysis of viral replication in vitro. As shown by our results, HIV-1<sub>IndieC1-mGL</sub> replicated with equal efficiency to the parental HIV-1<sub>IndieC1</sub> virus&#x02014;including in the infectivity assay using TZM-bl cells and a multiday replication assay in MDMs (<xref rid="viruses-16-01859-f002" ref-type="fig">Figure 2</xref> and <xref rid="viruses-16-01859-f003" ref-type="fig">Figure 3</xref>). We note that in spite of displaying infectivity levels that were similar to the parental virus, the reporter virus displayed a delayed peak productivity (3 days). While it is hard to pinpoint the mechanistic basis for this 3-day delay, one could imagine that the inserted sequences may affect the stability of chimeric viral genomic RNA. However, in the one month-long macrophage replication experiments we conducted (<xref rid="viruses-16-01859-f003" ref-type="fig">Figure 3</xref> and <xref rid="viruses-16-01859-f004" ref-type="fig">Figure 4</xref>), there were no observable defects. Not only did HIV-1<sub>IndieC1-mGL</sub> replicate with equal efficiency to the parental virus, but it also retained its lack of responsiveness to CCL2, which indicates that it also retains other characteristics of HIV-1<sub>indieC1</sub>. HIV-1<sub>IndieC1-mGL</sub> macrophage-tropic subtype C reporter virus complements the only other currently available subtype C reporter virus reported by Rai et al., which employed EGFP as a reporter and was based on K3016, a South African subtype C virus that could infect T cells and PBMCs [<xref rid="B34-viruses-16-01859" ref-type="bibr">34</xref>]. Thus, HIV-1<sub>IndieC1-mGL</sub> represents the only HIV-1<sub>IndieC1</sub>-derived virus with a fluorescence reporter.</p><p>The presence of three NF-&#x003ba;B binding sites in the LTR region of subtype C HIV-1 compared to only two NF-&#x003ba;B binding sites in most subtypes of HIV-1, including subtype B, suggest that HIV-1 subtype C may respond to Meth with a greater responsiveness than HIV-1 subtype B [<xref rid="B35-viruses-16-01859" ref-type="bibr">35</xref>]. Therefore, we examined the effect of Meth treatment on MDMs infected with recombinant HIV-1<sub>IndieC1-mGL</sub> and HIV-1<sub>NLAD8-GFP-Nef</sub> viruses. Our results revealed that the Meth treatment of MDMs infected with the HIV-1<sub>IndieC1-mGL</sub> reporter virus markedly increased the viral replication compared to that of the infected cultures that were left untreated. This increase was also observed in the parental virus HIV-1<sub>IndieC1</sub>. This increase was higher than that observed for HIV-1<sub>NLAD8-GFP-Nef</sub> compared to similarly infected untreated MDMs. As expected, Meth treatment of MDMs infected with the parental subtype B virus HIV-1<sub>ADA</sub> was comparable to that of HIV-1<sub>NLAD8-GFP-Nef</sub>.</p><p>Meth is known to contribute to the progression of AIDS by enhancing viral replication rates and the consequent ineffectiveness of antiretrovirals [<xref rid="B36-viruses-16-01859" ref-type="bibr">36</xref>]. In vitro, Meth increases viral replication in monocytes [<xref rid="B33-viruses-16-01859" ref-type="bibr">33</xref>,<xref rid="B37-viruses-16-01859" ref-type="bibr">37</xref>] and in CD4 T cells [<xref rid="B30-viruses-16-01859" ref-type="bibr">30</xref>], which can lead to increased viral load in HIV-1-positive active drug users. However, it must be emphasized that the increase in HIV-1 replication in CD4 T cells [<xref rid="B30-viruses-16-01859" ref-type="bibr">30</xref>] is controversial, as an earlier study showed that Meth inhibits of HIV-1 replication in T cells [<xref rid="B38-viruses-16-01859" ref-type="bibr">38</xref>]. Interestingly, both these studies used comparable Meth concentrations in activated CD4 T cells and used the same strain of HIV-1 (HIV-1<sub>BAL</sub>). Bosso et al. showed that the increase in HIV-1 replication observed in the presence of Meth is mediated by NF-kB enhancers in HIV-1 subtype B [<xref rid="B35-viruses-16-01859" ref-type="bibr">35</xref>].</p><p>Our results also indicate a dose-dependent response of Meth in inducing HIV-1 replication. We found that lower concentrations of Meth increase virus replication better. Previous reports have shown increases in HIV-1 replication upon Meth addition. One report studied the effect of Meth on the HIV-infected macrophages at a range of concentrations (1 &#x000b5;M to 250 &#x003bc;M) [<xref rid="B31-viruses-16-01859" ref-type="bibr">31</xref>]. Quantitation of HIV-1 RNA revealed that the highest increase in HIV by Meth was at 250 &#x003bc;M at 8 days post infection, an approximately two-fold increase over untreated, infected macrophages. In our experiments for HIV-1 subtype B virus, the highest increases in virus replication were observed at 100&#x000b5;M Meth (up to 3-fold higher) at 15 days post infection. At the higher concentrations of Meth tested (250 &#x000b5;M and 500 &#x000b5;m), the extent of inhibition was reduced to 2-fold or less. We do not know the basis for this type of dose response. Another study investigated the effect of Meth on the expression of the HIV genome in human microglia in vitro [<xref rid="B33-viruses-16-01859" ref-type="bibr">33</xref>]. They found that Meth treatment increased the transcriptional activity of the HIV-1 LTR promoter in a dose-dependent manner. In that study, Meth increased the activity and movement of the transcription factor NF-&#x003ba;B, which is a key player in transcriptional activation from HIV-1 LTR. Blocking NF-&#x003ba;B signaling prevented the Meth-induced activation of HIV-1 LTR. These findings suggest that Meth can directly stimulate HIV gene expression in microglial cells, the primary target cells for HIV-1 in the central nervous system, through NF-&#x003ba;B activation. These results support our finding of a much higher increase in the stimulation of viral replication at 100 &#x000b5;M Meth in the presence of 3 NF-&#x003ba;B sites in the LTR as in HIV-1 subtype C HIV-1.</p><p>Our mGreenLantern-tagged HIV-1<sub>IndieC1</sub> reporter virus can be beneficial for in vitro studies involving monocytes, microglia, and macrophages. Although we did not perform an exhaustive series of tests, minimally, the reporter virus retained the replication characteristics of its parental clone that were tested, which indicates that it can be used for cell culture and possibly in small animal models such as humanized mice. Using this reporter virus, we were able to detect the effects of Meth on HIV-1 replication of both subtype C and B in infected MDMs, where the responses to Meth of HIV-1 subtype C were higher than that of HIV-1 subtype B.</p></sec><sec sec-type="conclusions" id="sec5-viruses-16-01859"><title>5. Conclusions</title><p>We have shown that a mGreenLantern-tagged subtype C virus, that we constructed, is replication-competent and retains some of the characteristic features of subtype C that we tested and that its responsiveness to Meth treatment is more robust than subtype B. The infectious full-length recombinant mGreenLantern-tagged HIV-1<sub>IndieC1</sub> reporter virus can be an essential tool for understanding the intracellular pathways inside the cells that control the virus replication. Furthermore, it can be used for conducting HIV subtype C-specific research and investigating the viral and host factors influencing the rapidly expanding subtype C infections worldwide.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank Jonathan Karn for providing the plasmid of HIV-1<sub>NLAD8-GFP-Nef</sub>. In addition, the authors wish to thank Joshua Nosanchuk for Meth storage. The work reported here was supported by NIH grant R01.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.M. and V.R.P.; investigation, D.M., Y.L., A.G. and X.W.; writing&#x02014;original draft preparation, D.M. and V.R.P.; writing&#x02014;review and editing, A.M., Y.L., A.G., G.V.K. and V.R.P.; supervision, V.R.P. and G.V.K.; project administration, V.R.P.; funding acquisition, V.R.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study did not involve human subjects. Therefore, no institutional review board approval was required.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Following publication, the authors are willing to share all raw data that have been analyzed in the manuscript, and they will be made available to other researchers.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01859"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Julius</surname><given-names>P.</given-names></name>
<name><surname>Kang</surname><given-names>G.</given-names></name>
<name><surname>West</surname><given-names>J.T.</given-names></name>
<name><surname>Wood</surname><given-names>C.</given-names></name>
</person-group><article-title>Subtype C HIV-1 reservoirs throughout the body in ART-suppressed individuals</article-title><source>JCI Insight</source><year>2022</year><volume>7</volume><fpage>e162604</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.162604</pub-id><pub-id pub-id-type="pmid">36278485</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01859"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hemelaar</surname><given-names>J.</given-names></name>
<name><surname>Gouws</surname><given-names>E.</given-names></name>
<name><surname>Ghys</surname><given-names>P.D.</given-names></name>
<name><surname>Osmanov</surname><given-names>S.</given-names></name>
<collab>WHO-UNAIDS Network for HIV Isolation and Characterisation</collab>
</person-group><article-title>Global trends in molecular epidemiology of HIV-1 during 2000&#x02013;2007</article-title><source>AIDS</source><year>2011</year><volume>25</volume><fpage>679</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328342ff93</pub-id><pub-id pub-id-type="pmid">21297424</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01859"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ball</surname><given-names>S.C.</given-names></name>
<name><surname>Abraha</surname><given-names>A.</given-names></name>
<name><surname>Collins</surname><given-names>K.R.</given-names></name>
<name><surname>Marozsan</surname><given-names>A.J.</given-names></name>
<name><surname>Baird</surname><given-names>H.</given-names></name>
<name><surname>Quinones-Mateu</surname><given-names>M.E.</given-names></name>
<name><surname>Penn-Nicholson</surname><given-names>A.</given-names></name>
<name><surname>Murray</surname><given-names>M.</given-names></name>
<name><surname>Richard</surname><given-names>N.</given-names></name>
<name><surname>Lobritz</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>1021</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.2.1021-1038.2003</pub-id><pub-id pub-id-type="pmid">12502818</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01859"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tebit</surname><given-names>D.M.</given-names></name>
<name><surname>Nankya</surname><given-names>I.</given-names></name>
<name><surname>Arts</surname><given-names>E.J.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
</person-group><article-title>HIV diversity, recombination and disease progression: How does fitness &#x0201c;fit&#x0201d; into the puzzle?</article-title><source>AIDS Rev.</source><year>2007</year><volume>9</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">17694675</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01859"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cicala</surname><given-names>C.</given-names></name>
<name><surname>Arthos</surname><given-names>J.</given-names></name>
<name><surname>Fauci</surname><given-names>A.S.</given-names></name>
</person-group><article-title>HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV</article-title><source>J. Transl. Med.</source><year>2011</year><volume>9</volume><issue>(Suppl. S1)</issue><fpage>S2</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-9-S1-S2</pub-id><pub-id pub-id-type="pmid">21284901</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01859"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chikere</surname><given-names>K.</given-names></name>
<name><surname>Webb</surname><given-names>N.E.</given-names></name>
<name><surname>Chou</surname><given-names>T.</given-names></name>
<name><surname>Borm</surname><given-names>K.</given-names></name>
<name><surname>Sterjovski</surname><given-names>J.</given-names></name>
<name><surname>Gorry</surname><given-names>P.R.</given-names></name>
<name><surname>Lee</surname><given-names>B.</given-names></name>
</person-group><article-title>Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies</article-title><source>Retrovirology</source><year>2014</year><volume>11</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-11-48</pub-id><pub-id pub-id-type="pmid">24957778</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01859"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bachu</surname><given-names>M.</given-names></name>
<name><surname>Yalla</surname><given-names>S.</given-names></name>
<name><surname>Asokan</surname><given-names>M.</given-names></name>
<name><surname>Verma</surname><given-names>A.</given-names></name>
<name><surname>Neogi</surname><given-names>U.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Murali</surname><given-names>R.V.</given-names></name>
<name><surname>Mukthey</surname><given-names>A.B.</given-names></name>
<name><surname>Bhatt</surname><given-names>R.</given-names></name>
<name><surname>Chatterjee</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Multiple NF-&#x003ba;B sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>44714</fpage><lpage>44735</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.397158</pub-id><pub-id pub-id-type="pmid">23132857</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01859"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Obasa</surname><given-names>A.E.</given-names></name>
<name><surname>Ambikan</surname><given-names>A.T.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Neogi</surname><given-names>U.</given-names></name>
<name><surname>Jacobs</surname><given-names>G.B.</given-names></name>
</person-group><article-title>Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa</article-title><source>BMC Infect. Dis.</source><year>2021</year><volume>21</volume><elocation-id>214</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-021-05905-2</pub-id><pub-id pub-id-type="pmid">33632139</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01859"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freed</surname><given-names>E.O.</given-names></name>
</person-group><article-title>Viral late domains</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>4679</fpage><lpage>4687</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.10.4679-4687.2002</pub-id><pub-id pub-id-type="pmid">11967285</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01859"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marlowe</surname><given-names>N.</given-names></name>
<name><surname>Flys</surname><given-names>T.</given-names></name>
<name><surname>Hackett</surname><given-names>J.</given-names><suffix>Jr.</suffix></name>
<name><surname>Schumaker</surname><given-names>M.</given-names></name>
<name><surname>Jackson</surname><given-names>J.B.</given-names></name>
<name><surname>Eshleman</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strains</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2004</year><volume>20</volume><fpage>1119</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1089/aid.2004.20.1119</pub-id><pub-id pub-id-type="pmid">15585104</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01859"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Aralaguppe</surname><given-names>S.G.</given-names></name>
<name><surname>Abrahams</surname><given-names>M.R.</given-names></name>
<name><surname>Williamson</surname><given-names>C.</given-names></name>
<name><surname>Gray</surname><given-names>C.</given-names></name>
<name><surname>Balakrishnan</surname><given-names>P.</given-names></name>
<name><surname>Saravanan</surname><given-names>S.</given-names></name>
<name><surname>Murugavel</surname><given-names>K.G.</given-names></name>
<name><surname>Solomon</surname><given-names>S.</given-names></name>
<name><surname>Ranga</surname><given-names>U.</given-names></name>
</person-group><article-title>The PTAP sequence duplication in HIV-1 subtype C Gag p6 in drug-naive subjects of India and South Africa</article-title><source>BMC Infect. Dis.</source><year>2017</year><volume>17</volume><elocation-id>95</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-017-2184-4</pub-id><pub-id pub-id-type="pmid">28118816</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01859"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ajasin</surname><given-names>D.O.</given-names></name>
<name><surname>Rao</surname><given-names>V.R.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Ramasamy</surname><given-names>S.</given-names></name>
<name><surname>Pujato</surname><given-names>M.</given-names></name>
<name><surname>Ruiz</surname><given-names>A.P.</given-names></name>
<name><surname>Fiser</surname><given-names>A.</given-names></name>
<name><surname>Bresnick</surname><given-names>A.R.</given-names></name>
<name><surname>Kalpana</surname><given-names>G.V.</given-names></name>
<name><surname>Prasad</surname><given-names>V.R.</given-names></name>
</person-group><article-title>CCL2 mobilizes ALIX to facilitate Gag-p6 mediated HIV-1 virion release</article-title><source>Elife</source><year>2019</year><volume>8</volume><fpage>e35546</fpage><pub-id pub-id-type="doi">10.7554/eLife.35546</pub-id><pub-id pub-id-type="pmid">31172941</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01859"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patil</surname><given-names>A.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>J.</given-names></name>
</person-group><article-title>Natural deletion of L35Y36 in p6 gag eliminate LYPXnL/ALIX auxiliary virus release pathway in HIV-1 subtype C</article-title><source>Virus Res.</source><year>2012</year><volume>170</volume><fpage>154</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2012.08.020</pub-id><pub-id pub-id-type="pmid">22981647</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01859"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neogi</surname><given-names>U.</given-names></name>
<name><surname>Rao</surname><given-names>S.D.</given-names></name>
<name><surname>Bontell</surname><given-names>I.</given-names></name>
<name><surname>Verheyen</surname><given-names>J.</given-names></name>
<name><surname>Rao</surname><given-names>V.R.</given-names></name>
<name><surname>Gore</surname><given-names>S.C.</given-names></name>
<name><surname>Soni</surname><given-names>N.</given-names></name>
<name><surname>Shet</surname><given-names>A.</given-names></name>
<name><surname>Schulter</surname><given-names>E.</given-names></name>
<name><surname>Ekstrand</surname><given-names>M.L.</given-names></name>
<etal/>
</person-group><article-title>Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients</article-title><source>AIDS</source><year>2014</year><volume>28</volume><fpage>2319</fpage><lpage>2322</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000419</pub-id><pub-id pub-id-type="pmid">25102091</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01859"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ranga</surname><given-names>U.</given-names></name>
<name><surname>Shankarappa</surname><given-names>R.</given-names></name>
<name><surname>Siddappa</surname><given-names>N.B.</given-names></name>
<name><surname>Ramakrishna</surname><given-names>L.</given-names></name>
<name><surname>Nagendran</surname><given-names>R.</given-names></name>
<name><surname>Mahalingam</surname><given-names>M.</given-names></name>
<name><surname>Mahadevan</surname><given-names>A.</given-names></name>
<name><surname>Jayasuryan</surname><given-names>N.</given-names></name>
<name><surname>Satishchandra</surname><given-names>P.</given-names></name>
<name><surname>Shankar</surname><given-names>S.K.</given-names></name>
<etal/>
</person-group><article-title>Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>2586</fpage><lpage>2590</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.5.2586-2590.2004</pub-id><pub-id pub-id-type="pmid">14963162</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01859"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cavrois</surname><given-names>M.</given-names></name>
<name><surname>De Noronha</surname><given-names>C.</given-names></name>
<name><surname>Greene</surname><given-names>W.C.</given-names></name>
</person-group><article-title>A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes</article-title><source>Nat. Biotechnol.</source><year>2002</year><volume>20</volume><fpage>1151</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1038/nbt745</pub-id><pub-id pub-id-type="pmid">12355096</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01859"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Burdick</surname><given-names>R.C.</given-names></name>
<name><surname>Nagashima</surname><given-names>K.</given-names></name>
<name><surname>Hu</surname><given-names>W.S.</given-names></name>
<name><surname>Pathak</surname><given-names>V.K.</given-names></name>
</person-group><article-title>HIV-1 cores retain their integrity until minutes before uncoating in the nucleus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2019467118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2019467118</pub-id><pub-id pub-id-type="pmid">33649225</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01859"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Bieniasz</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Single-Cell and Single-Cycle Analysis of HIV-1 Replication</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1004961</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004961</pub-id><pub-id pub-id-type="pmid">26086614</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01859"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>E.M.</given-names></name>
<name><surname>Perez</surname><given-names>O.</given-names></name>
<name><surname>Melar</surname><given-names>M.</given-names></name>
<name><surname>Hope</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell</article-title><source>Virology</source><year>2007</year><volume>360</volume><fpage>286</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.10.025</pub-id><pub-id pub-id-type="pmid">17123568</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01859"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirui</surname><given-names>J.</given-names></name>
<name><surname>Freed</surname><given-names>E.O.</given-names></name>
</person-group><article-title>Generation and validation of a highly sensitive bioluminescent HIV-1 reporter vector that simplifies measurement of virus release</article-title><source>Retrovirology</source><year>2020</year><volume>17</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s12977-020-00521-5</pub-id><pub-id pub-id-type="pmid">32430080</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01859"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hashemi</surname><given-names>F.B.</given-names></name>
<name><surname>Barreto</surname><given-names>K.</given-names></name>
<name><surname>Bernhard</surname><given-names>W.</given-names></name>
<name><surname>Hashemi</surname><given-names>P.</given-names></name>
<name><surname>Lomness</surname><given-names>A.</given-names></name>
<name><surname>Sadowski</surname><given-names>I.</given-names></name>
</person-group><article-title>HIV Provirus Stably Reproduces Parental Latent and Induced Transcription Phenotypes Regardless of the Chromosomal Integration Site</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>5302</fpage><lpage>5314</lpage><pub-id pub-id-type="doi">10.1128/JVI.02842-15</pub-id><pub-id pub-id-type="pmid">26984732</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01859"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wires</surname><given-names>E.S.</given-names></name>
<name><surname>Alvarez</surname><given-names>D.</given-names></name>
<name><surname>Dobrowolski</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Morales</surname><given-names>M.</given-names></name>
<name><surname>Karn</surname><given-names>J.</given-names></name>
<name><surname>Harvey</surname><given-names>B.K.</given-names></name>
</person-group><article-title>Methamphetamine activates nuclear factor &#x003ba;-light-chain-enhancer of activated B cells (NF-&#x003ba;B) and induces human immunodeficiency virus (HIV) transcription in human microglial cells</article-title><source>J. NeuroVirology</source><year>2012</year><volume>18</volume><fpage>400</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1007/s13365-012-0103-4</pub-id><pub-id pub-id-type="pmid">22618514</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01859"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mochizuki</surname><given-names>N.</given-names></name>
<name><surname>Otsuka</surname><given-names>N.</given-names></name>
<name><surname>Matsuo</surname><given-names>K.</given-names></name>
<name><surname>Shiino</surname><given-names>T.</given-names></name>
<name><surname>Kojima</surname><given-names>A.</given-names></name>
<name><surname>Kurata</surname><given-names>T.</given-names></name>
<name><surname>Sakai</surname><given-names>K.</given-names></name>
<name><surname>Yamamoto</surname><given-names>N.</given-names></name>
<name><surname>Isomura</surname><given-names>S.</given-names></name>
<name><surname>Dhole</surname><given-names>T.N.</given-names></name>
<etal/>
</person-group><article-title>An infectious DNA clone of HIV type 1 subtype C</article-title><source>AIDS Res. Hum. Retroviruses</source><year>1999</year><volume>15</volume><fpage>1321</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1089/088922299310223</pub-id><pub-id pub-id-type="pmid">10505681</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01859"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ho</surname><given-names>S.N.</given-names></name>
<name><surname>Hunt</surname><given-names>H.D.</given-names></name>
<name><surname>Horton</surname><given-names>R.M.</given-names></name>
<name><surname>Pullen</surname><given-names>J.K.</given-names></name>
<name><surname>Pease</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Site-directed mutagenesis by overlap extension. using the polymerase chain reaction</article-title><source>Gene</source><year>1989</year><volume>77</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(89)90358-2</pub-id><pub-id pub-id-type="pmid">2744487</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01859"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>B.C.</given-names></name>
<name><surname>Nabel</surname><given-names>E.M.</given-names></name>
<name><surname>Murdock</surname><given-names>M.H.</given-names></name>
<name><surname>Lao-Peregrin</surname><given-names>C.</given-names></name>
<name><surname>Tsoulfas</surname><given-names>P.</given-names></name>
<name><surname>Blackmore</surname><given-names>M.G.</given-names></name>
<name><surname>Lee</surname><given-names>F.S.</given-names></name>
<name><surname>Liston</surname><given-names>C.</given-names></name>
<name><surname>Morishita</surname><given-names>H.</given-names></name>
<name><surname>Petsko</surname><given-names>G.A.</given-names></name>
</person-group><article-title>mGreenLantern: A bright monomeric fluorescent protein with rapid expression and cell filling properties for neuronal imaging</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>30710</fpage><lpage>30721</lpage><pub-id pub-id-type="doi">10.1073/pnas.2000942117</pub-id><pub-id pub-id-type="pmid">33208539</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01859"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dejosez</surname><given-names>M.</given-names></name>
<name><surname>Levine</surname><given-names>S.S.</given-names></name>
<name><surname>Frampton</surname><given-names>G.M.</given-names></name>
<name><surname>Whyte</surname><given-names>W.A.</given-names></name>
<name><surname>Stratton</surname><given-names>S.A.</given-names></name>
<name><surname>Barton</surname><given-names>M.C.</given-names></name>
<name><surname>Gunaratne</surname><given-names>P.H.</given-names></name>
<name><surname>Young</surname><given-names>R.A.</given-names></name>
<name><surname>Zwaka</surname><given-names>T.P.</given-names></name>
</person-group><article-title>Ronin/Hcf-1 binds to a hyperconserved enhancer element and regulates genes involved in the growth of embryonic stem cells</article-title><source>Genes Dev.</source><year>2010</year><volume>24</volume><fpage>1479</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1101/gad.1935210</pub-id><pub-id pub-id-type="pmid">20581084</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01859"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theodore</surname><given-names>T.S.</given-names></name>
<name><surname>Englund</surname><given-names>G.</given-names></name>
<name><surname>BucklerWhite</surname><given-names>A.</given-names></name>
<name><surname>Buckler</surname><given-names>C.E.</given-names></name>
<name><surname>Martin</surname><given-names>M.A.</given-names></name>
<name><surname>Peden</surname><given-names>K.W.C.</given-names></name>
</person-group><article-title>Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions</article-title><source>AIDS Res. Hum. Retroviruses</source><year>1996</year><volume>12</volume><fpage>191</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1089/aid.1996.12.191</pub-id><pub-id pub-id-type="pmid">8835195</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01859"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cenker</surname><given-names>J.J.</given-names></name>
<name><surname>Stultz</surname><given-names>R.D.</given-names></name>
<name><surname>McDonald</surname><given-names>D.</given-names></name>
</person-group><article-title>Brain Microglial Cells Are Highly Susceptible to HIV-1 Infection and Spread</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2017</year><volume>33</volume><fpage>1155</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1089/aid.2017.0004</pub-id><pub-id pub-id-type="pmid">28486838</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01859"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derdeyn</surname><given-names>C.A.</given-names></name>
<name><surname>Decker</surname><given-names>J.M.</given-names></name>
<name><surname>Sfakianos</surname><given-names>J.N.</given-names></name>
<name><surname>Wu</surname><given-names>X.Y.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>W.A.</given-names></name>
<name><surname>Ratner</surname><given-names>L.</given-names></name>
<name><surname>Kappes</surname><given-names>J.C.</given-names></name>
<name><surname>Shaw</surname><given-names>G.M.</given-names></name>
<name><surname>Hunter</surname><given-names>E.</given-names></name>
</person-group><article-title>Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>8358</fpage><lpage>8367</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.18.8358-8367.2000</pub-id><pub-id pub-id-type="pmid">10954535</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01859"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantuzzi</surname><given-names>L.</given-names></name>
<name><surname>Spadaro</surname><given-names>F.</given-names></name>
<name><surname>Vallanti</surname><given-names>G.</given-names></name>
<name><surname>Canini</surname><given-names>I.</given-names></name>
<name><surname>Ramoni</surname><given-names>C.</given-names></name>
<name><surname>Vicenzi</surname><given-names>E.</given-names></name>
<name><surname>Belardelli</surname><given-names>F.</given-names></name>
<name><surname>Poli</surname><given-names>G.</given-names></name>
<name><surname>Gessani</surname><given-names>S.</given-names></name>
</person-group><article-title>Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages</article-title><source>Blood</source><year>2003</year><volume>102</volume><fpage>2334</fpage><lpage>2337</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-10-3275</pub-id><pub-id pub-id-type="pmid">12805068</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01859"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>A.</given-names></name>
<name><surname>Kulkarni</surname><given-names>R.</given-names></name>
<name><surname>Shrivastava</surname><given-names>A.</given-names></name>
<name><surname>Jiang</surname><given-names>S.X.</given-names></name>
<name><surname>Lawson</surname><given-names>K.</given-names></name>
<name><surname>Groopman</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Methamphetamine functions as a novel CD4<sup>+</sup> T-cell activator via the sigma-1 receptor to enhance HIV-1 infection</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>958</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-35757-x</pub-id><pub-id pub-id-type="pmid">30700725</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01859"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Song</surname><given-names>L.</given-names></name>
<name><surname>Ye</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>S.H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.J.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Ho</surname><given-names>W.Z.</given-names></name>
</person-group><article-title>Methamphetamine enhances HIV infection of macrophages</article-title><source>Am. J. Pathol.</source><year>2008</year><volume>172</volume><fpage>1617</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2008.070971</pub-id><pub-id pub-id-type="pmid">18458095</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01859"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toussi</surname><given-names>S.S.</given-names></name>
<name><surname>Joseph</surname><given-names>A.</given-names></name>
<name><surname>Zheng</surname><given-names>J.H.</given-names></name>
<name><surname>Dutta</surname><given-names>M.</given-names></name>
<name><surname>Santambrogio</surname><given-names>L.</given-names></name>
<name><surname>Goldstein</surname><given-names>H.</given-names></name>
</person-group><article-title>Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2009</year><volume>25</volume><fpage>1117</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1089/aid.2008.0282</pub-id><pub-id pub-id-type="pmid">19895343</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01859"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rai</surname><given-names>M.</given-names></name>
<name><surname>Timilsina</surname><given-names>U.</given-names></name>
<name><surname>Gaur</surname><given-names>R.</given-names></name>
</person-group><article-title>Construction and characterization of a full-length, replication-competent and infectious enhanced green fluorescence protein-tagged HIV-1 subtype C molecular clone</article-title><source>Virology</source><year>2022</year><volume>571</volume><fpage>34</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2022.04.003</pub-id><pub-id pub-id-type="pmid">35460960</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01859"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bosso</surname><given-names>M.</given-names></name>
<name><surname>Sturzel</surname><given-names>C.M.</given-names></name>
<name><surname>Kmiec</surname><given-names>D.</given-names></name>
<name><surname>Badarinarayan</surname><given-names>S.S.</given-names></name>
<name><surname>Braun</surname><given-names>E.</given-names></name>
<name><surname>Ito</surname><given-names>J.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Hahn</surname><given-names>B.H.</given-names></name>
<name><surname>Sparrer</surname><given-names>K.M.J.</given-names></name>
<name><surname>Sauter</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>An additional NF-&#x003ba;B site allows HIV-1 subtype C to evade restriction by nuclear PYHIN proteins</article-title><source>Cell Rep.</source><year>2021</year><volume>36</volume><fpage>109735</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109735</pub-id><pub-id pub-id-type="pmid">34551301</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01859"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Childers</surname><given-names>M.E.</given-names></name>
<name><surname>Cherner</surname><given-names>M.</given-names></name>
<name><surname>Lazzaretto</surname><given-names>D.</given-names></name>
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<collab>The HIV Neurobehavioral Research Center Group</collab>
</person-group><article-title>Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>188</volume><fpage>1820</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1086/379894</pub-id><pub-id pub-id-type="pmid">14673760</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01859"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skowronska</surname><given-names>M.</given-names></name>
<name><surname>McDonald</surname><given-names>M.</given-names></name>
<name><surname>Velichkovska</surname><given-names>M.</given-names></name>
<name><surname>Leda</surname><given-names>A.R.</given-names></name>
<name><surname>Park</surname><given-names>M.</given-names></name>
<name><surname>Toborek</surname><given-names>M.</given-names></name>
</person-group><article-title>Methamphetamine increases HIV infectivity in neural progenitor cells</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>296</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA117.000795</pub-id><pub-id pub-id-type="pmid">29158267</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01859"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mantri</surname><given-names>C.K.</given-names></name>
<name><surname>Mantri</surname><given-names>J.V.</given-names></name>
<name><surname>Pandhare</surname><given-names>J.</given-names></name>
<name><surname>Dash</surname><given-names>C.</given-names></name>
</person-group><article-title>Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression</article-title><source>Am. J. Pathol.</source><year>2014</year><volume>184</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.09.011</pub-id><pub-id pub-id-type="pmid">24434277</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01859-f001"><label>Figure 1</label><caption><p>Schematic representation of the mGreenLantern expressing HIV-1 subtype C reporter virus in comparison with the parental HIV-1<sub>IndieC1 virus</sub>. All of the open-reading frames (<italic toggle="yes">gag</italic> (1476 nt), <italic toggle="yes">pol</italic> (3000 nt), <italic toggle="yes">vif</italic> (579 nt), <italic toggle="yes">rev1</italic> (75 nt), <italic toggle="yes">tat1</italic> (216 nt), <italic toggle="yes">vpu</italic> (249 nt), <italic toggle="yes">vpr</italic> (291 nt), <italic toggle="yes">env</italic> (2574 nt), <italic toggle="yes">tat2</italic> (90 nt), <italic toggle="yes">rev2</italic> (228 nt), <italic toggle="yes">mGreenLantern</italic> (720 nt), and <italic toggle="yes">Nef</italic> (624 nt)) are shown as boxes and labeled as such. An IRES sequence (shown as a horizontal thick line upstream of nef) was inserted at5&#x02032; of the <italic toggle="yes">Nef</italic> gene to facilitate its expression.</p></caption><graphic xlink:href="viruses-16-01859-g001" position="float"/></fig><fig position="float" id="viruses-16-01859-f002"><label>Figure 2</label><caption><p>Infectivity of HIV-1 subtype C and B viruses measured by luciferase assay in TZM-bl cells. TZM-bl cells were infected with HIV-1 subtype C and B with different MOI (500, 250, 125, 62.5, and 31.25 ng p24/2 &#x000d7; 10<sup>5</sup> cells) and incubated at 37 &#x000b0;C with 5% CO<sub>2</sub> for 24 h. (<bold>A</bold>) Infectivity of recombinant HIV-1<sub>IndieC1-mGL</sub> reporter virus measured alongside the parental HIV-1<sub>IndieC1</sub>. (<bold>B</bold>) Infectivity of recombinant HIV-<sub>1NLAD8-GFP-Nef</sub> measured alongside HIV-1<sub>ADA</sub>. Data are represented as mean &#x000b1; SEM (<italic toggle="yes">n</italic> = 3).</p></caption><graphic xlink:href="viruses-16-01859-g002" position="float"/></fig><fig position="float" id="viruses-16-01859-f003"><label>Figure 3</label><caption><p>Measurement of replication efficiency of HIV-1 (subtype B and subtype C) using a multi-day replication assay in MDMs. MDMs (10 ng/1 &#x000d7; 10<sup>6</sup>) were infected with either subtype C or subtype B viruses. (<bold>A</bold>) The replication competence of recombinant HIV-1<sub>IndieC1-mGL</sub> reporter virus was compared to the parental virus, HIV-1<sub>IndieC1</sub>. (<bold>B</bold>) The replication competence of recombinant HIV-1<sub>NLAD8-GFP-Nef was</sub> compared to HIV-1<sub>ADA</sub>. Data are a mean of three experiments &#x000b1; SEM (<italic toggle="yes">n</italic> = 3).</p></caption><graphic xlink:href="viruses-16-01859-g003" position="float"/></fig><fig position="float" id="viruses-16-01859-f004"><label>Figure 4</label><caption><p>Effect of CCL2 on HIV-1 subtype C and B replication in MDMs. (<bold>A</bold>) MDMs were infected with HIV-1<sub>IndieC1-mGL</sub> reporter virus (<bold>Left</bold>) or HIV-1<sub>NLAD8-GFP-Nef</sub> (<bold>Right</bold>) and treated with CCL2, anti-CCL2, or isotype control antibody (see Methods). UT = no treatment. (<bold>B</bold>) Tracking the effect of CCL2 or anti-CCL2 on HIV-1<sub>IndieC1-mGL</sub> reporter replication via fluorescence intensity. (<bold>C</bold>) Tracking the effect of CCL2 or anti-CCL2 on HIV-1<sub>NLAD8-GFP-Nef</sub> replication in MDMs using fluorescence intensity. dpi, days post infection. Scale bar for (<bold>B</bold>,<bold>C</bold>) is as in the panel anti-CCL2, 30 dpi. (<bold>D</bold>) Measurement of fluorescence intensity in panels (<bold>B</bold>,<bold>C</bold>) for subtype C or subtype B reporter viruses with various treatments. Data are a mean of three experiments &#x000b1; SEM (<italic toggle="yes">n</italic> = 3).</p></caption><graphic xlink:href="viruses-16-01859-g004" position="float"/></fig><fig position="float" id="viruses-16-01859-f005"><label>Figure 5</label><caption><p>Effect of Meth on HIV-1 replication. (<bold>A</bold>) Differential effect of Meth on HIV-1 subtype C (<bold>top panels</bold>) and subtype B (<bold>bottom panels</bold>) replication in MDMs. MDMs (10 ng/1 &#x000d7; 10<sup>6</sup>) were infected with subtype C or B viruses and treated with Meth at 100, 250, or 500 &#x003bc;M or not treated (0 &#x000b5;M). Replication of HIV-1<sub>IndieC1</sub> (<bold>top left</bold>); HIV-1<sub>IndieC1-mGL</sub> reporter (<bold>top right</bold>); HIV-1<sub>ADA</sub> (<bold>bottom left</bold>) and HIV-1<sub>NLAD8-GFP-Nef</sub> (<bold>bottom right</bold>) in the presence or absence of Meth as measured via p24 levels at 15 dpi. <italic toggle="yes">p</italic>: *, 0.05; **, &#x0003c;0.01; ***, &#x0003c;0.001; and ****, &#x0003c;0.0001. (<bold>B</bold>) Tracking the effect of Meth on HIV-1<sub>IndieC1-mGL</sub> or HIV-1<sub>NLAD8-GFP-Nef</sub> via green fluorescence intensity. (<bold>C</bold>) Measurement of fluorescence intensity to determine effect of Meth on HIV-1 replication from Panel B. Shows plots of fluorescence intensity for HIV-1<sub>IndieC1-mGL</sub> (<bold>left</bold>) and HIV-1<sub>NLAD8-GFP-Nef</sub> (<bold>right</bold>). Data are a mean of three experiments &#x000b1; SEM (<italic toggle="yes">n</italic> = 3). Scale bar = 10 &#x000b5;m. <italic toggle="yes">p</italic>: *, 0.05; **, &#x0003c;0.01; ***, &#x0003c;0.001; and ****, &#x0003c;0.0001.</p></caption><graphic xlink:href="viruses-16-01859-g005" position="float"/></fig><table-wrap position="float" id="viruses-16-01859-t001"><object-id pub-id-type="pii">viruses-16-01859-t001_Table 1</object-id><label>Table 1</label><caption><p>List of primers used in overlap PCR to build the <italic toggle="yes">Pac1</italic>-gp160-mGreenLantern-IRES-Nef-LTR-<italic toggle="yes">AatII</italic> fragment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Item</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name of Primer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence of Primer </th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 1 (Forward)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;GGTTAATTAAAAGAATTAGGGAAAGAGCAG 3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 1 (Reverse)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;CCCTTGCTCACCATTATTATTTTATTGCAAAGCTGCTTCAAAGC 3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 2 (Forward)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;GCTTTGCAATAAAATAATAATGGTGAGCAAGGGCGAGGAGC 3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 2 (Reverse)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;AGCGGCTTCGGCCAGTAACGTTTACTTGTACAGCTCGTCC 3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 3 (Forward)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;TGGACGAGCTGTACAAGTAAACGTTACTGGCCGAAGCCGC 3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 3 (Reverse)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;TTTGACCACTTGCCCCCCATTATTATCATCGTGTTTTTCAAAG3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 4 (Forward)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;TTGAAAAACACGATGATAATAATGGGGGGCAAGTGGTCAAAATG3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 4 (Reverse)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;CGGAAAGTCCCTTCTGTGTCAGCAGTCTTTGTAAAACTCCGG3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Fragment 5 (Forward)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032;CCGGAGTTTTACAAAGACTGCTGACACAGAAGGGACTTTCCG3&#x02032;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fragment 5 (Reverse)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02032;GGTGGTGACGTCAGGTGGCACTTTTCGGGG 3&#x02032;</td></tr></tbody></table></table-wrap></floats-group></article>